ClinicalTrials.gg
CompletedNCT01214421TEMPO 4/4Updated Oct 25, 2021Results posted

Tolvaptan Extension Study in Participants With ADPKD

A Phase 3 interventional study of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 97 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-25.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2010, registered Sep 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,083
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
4th of 18
1,083 · median 91
Started
2010
with 3 others
Phase 3
8 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
9 of 18
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 4th largest by enrollment, is one of 4 that started in 2010, is one of 8 in phase 3, and was the 6th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from Baseline (from Study 156-04-251) in total kidney volume (TKV) and renal function.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Keywords

  • Kidney Disease
  • ADPKD
  • Autosomal Dominant Polycystic Kidney Disease
  • Adult Polycystic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who had successfully completed a Phase 1, 2, or 3 tolvaptan ADPKD or renal impairment study, with a confirmed diagnosis of ADPKD from prior studies [either 156-04-251 (NCT00428948) or 156-04-250 (NCT00413777), 156-06-260, 156-09-284 (NCT01336972), 156-09-285 (NCT01210560), and 156-09-290 (NCT01451827)].

Exclusion criteria

Exclusion Criteria:

  • Participants unable to provide written .
  • Participants (men or women) would not adhere to the reproductive precautions as outlined in the Informed Consent Form.
  • Participants (women only) with a positive urine pregnancy test.
  • Participants who were pregnant or breast-feeding.
  • Participants unable to take oral medications.
  • Participants who had allergic reactions to tolvaptan or chemically related structures such as benzazepines (benzazepril, conivaptan, fenoldopam mesylate, or mirtazapine).
  • Participants with disorders in thirst recognition or an inability to access fluids.
  • Participants with critical electrolyte imbalances, as determined by the investigator
  • Participants with or at risk of significant hypovolemia, as determined by investigator.
  • Participants with significant anemia, as determined by investigator.
  • Participants with a history of substance abuse (within the last 3 years).
  • Participants who were taking other experimental (that is, non-marketed) therapies or were participating in another clinical drug or device study; participating in the off-drug follow-up period of another ADPKD trial with tolvaptan was permitted.
  • Participants unable to complete magnetic resonance imaging (MRI) assessments (for example, participants with ferro-magnetic prostheses, aneurysm clips, severe claustrophobia).
  • Participants who had taken a vasopressin antagonist (outside of previous participation in a tolvaptan study).
  • Participants unable to comply with anti-hypertensive or other important medical therapy.
  • Participants with advanced diabetes.
  • Participants who were taking medications or had an illness that could confound endpoint assessments (including taking approved therapies for the purpose of affecting polycystic kidney disease [PKD] cysts).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,083 participants (actual)

Study arms

  • Experimental
    Tolvaptan

    Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 milligrams (mg) in the morning \[AM\]/15 mg in the evening \[PM\] titrated to 60 mg \[AM\]/30 mg \[PM\], then 90 mg \[AM\]/30 mg \[PM\] based on tolerability were given orally twice daily until the last participant originating from prior studies (either 156-04-251 or 156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290) who was eligible for efficacy analysis completed the Month 24.

    Drug: Tolvaptan

Interventions

  • Tablets of 15 or 30 mg

    Also known as: OPC-41061, Jinarc

06

What researchers measure

Primary outcomes

  1. Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)

    Total kidney volume is a measure of disease progression in the ADPKD participants. Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, radiologists used proprietary software to measure the volume of both kidneys in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). The percent change in the volume of both kidneys combined was analysed using mixed-effect model repeated measures (MMRM) analysis and reported. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.

    Time frame: Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)

Secondary outcomes

  1. Change From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)

    Estimated Glomerular Filtration Rate (eGFR) according to CKD-EPI is calculated using the CKD-EPI equation, expressed as a single equation, is GFR = 141 × min (serum creatinine \[Scr\]/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993 Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1 in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in eGFR for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). MMRM was used for the analysis. This outcome measure was analyzed only in the participants enrolled from the previous - 156-04-251, as pre-specified in the protocol.

    Time frame: Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)

  2. Annualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-271

    Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing annualized slope of TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.

    Time frame: Study Baseline (Prior to Day 1 in Study 156-08-271) to Month 24 in this study (Study 156-08-271)

  3. Annualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271

    Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (CKD-EPI) (divided by each participant's years of participation) for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.

    Time frame: Study Baseline (Prior to Day 1 in Study 156-08-271) to Month 24 (Study 156-08-271)

  4. Annualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271

    Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of TKV for the participants who received placebo in previous study (156-04-251) to annualized slope of TKV for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 and who received placebo in the previous study, as pre-specified in the protocol.

    Time frame: Tolvaptan, Delayed Treated: Baseline to Month 24 in Study 156-08-271; Placebo: Baseline to Month 36 in Study 156-04-251

  5. Annualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271

    Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (calculated using CKD-EPI formula) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of eGFR (CKD-EPI) for the participants who received placebo in previous study (156-04-251) to the annualized slope of eGFR (CKD-EPI) for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 who received placebo in previous study and received tolvaptan in this study, as pre-specified in the protocol.

    Time frame: Tolvaptan, Delayed Treated: Baseline to Month 24 in Study 156-08-271; Placebo: Baseline to Month 36 in Study 156-04-251

07

Results

Posted Oct 25, 2021
Limitations and caveats
The trial did not meet its primary endpoint as both groups showed similar decreases in the rate of TKV growth due in part to unforeseen limitations in the trial design. However, early-treatment resulted in cumulative improvements in renal function.

Participant flow

This study was conducted at 106 sites in 13 countries from 26 May 2010 to 29 Feb 2016. Eligible participants with autosomal dominant polycystic kidney disease (ADPKD) or renal impairment who completed previous tolvaptan treatment in studies: 156-04-251 (NCT00428948), 156-04-250 (NCT00413777), 156-06-260, 156-09-284 (NCT01336972), 156-09-285 (NCT01210560), and 156-09-290 (NCT01451827) were enrolled in this open-label study.

Participant flow — Overall Study
MilestoneTolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)Tolvaptan (From Other Studies: Tolvaptan, Early Treated)Tolvaptan (From Other Studies: Placebo, Delayed Treated)
Started55731418131
Completed50725614322
Not completed5058389
Withdrew: Lost to follow-up7373
Withdrew: Adverse event1635143
Withdrew: Sponsor discontinued site1200
Withdrew: Withdrawal criteria met3021
Withdrew: Physician decision2040
Withdrew: Withdrawal by subject2118112

Outcome measures

PrimaryPercent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)

Total kidney volume is a measure of disease progression in the ADPKD participants. Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, radiologists used proprietary software to measure the volume of both kidneys in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). The percent change in the volume of both kidneys combined was analysed using mixed-effect model repeated measures (MMRM) analysis and reported. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.

Time frame:
Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)
Reported as:
Mean · percent change
Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)
percent changeTolvaptan, Early Treated (From Study 156-04-251: Tolvaptan)Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo)
Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)28.66 ± 26.1430.58 ± 27.21
Statistical analysis
  • Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) vs Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) · Mixed Models Analysis · p = 0.358 · Ratio of geometric means (final values): 0.99 · 95% CI 0.96 to 1.02
SecondaryChange From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)

Estimated Glomerular Filtration Rate (eGFR) according to CKD-EPI is calculated using the CKD-EPI equation, expressed as a single equation, is GFR = 141 × min (serum creatinine \[Scr\]/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993 Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1 in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in eGFR for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). MMRM was used for the analysis. This outcome measure was analyzed only in the participants enrolled from the previous - 156-04-251, as pre-specified in the protocol.

Time frame:
Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)
Reported as:
Least squares mean · mL/min/1.73 square meters (m^2)
Change From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)
mL/min/1.73 square meters (m^2)Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan)Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo)
Change From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)-16.77 ± 13.16-19.92 ± 16.40
Statistical analysis
  • Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) vs Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) · Mixed Models Analysis · p = 0.0003 · Ls mean difference (final values): 3.15 · 95% CI 1.462 to 4.836
SecondaryAnnualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-271

Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing annualized slope of TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.

Time frame:
Study Baseline (Prior to Day 1 in Study 156-08-271) to Month 24 in this study (Study 156-08-271)
Reported as:
Number · percent change in TKV/participant-years
Annualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-271
percent change in TKV/participant-yearsTolvaptan, Early Treated (From Study 156-04-251: Tolvaptan)Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo)
Annualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-2716.1644.960
Statistical analysis
  • Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) vs Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) · Mixed Models Analysis · p = 0.0462 · Ratio of geometric means (final values): 1.011 · 95% CI 1.000 to 1.023
SecondaryAnnualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271

Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (CKD-EPI) (divided by each participant's years of participation) for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.

Time frame:
Study Baseline (Prior to Day 1 in Study 156-08-271) to Month 24 (Study 156-08-271)
Reported as:
Number · ml/min/1.73m^2/participant-years
Annualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271
ml/min/1.73m^2/participant-yearsTolvaptan, Early Treated (From Study 156-04-251: Tolvaptan)Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo)
Annualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271-3.255-3.142
Statistical analysis
  • Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) vs Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) · Mixed Models Analysis · p = 0.7259 · Ratio of geometric means (final values): -0.113 · 95% CI -0.746 to 0.520
SecondaryAnnualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271

Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of TKV for the participants who received placebo in previous study (156-04-251) to annualized slope of TKV for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 and who received placebo in the previous study, as pre-specified in the protocol.

Time frame:
Tolvaptan, Delayed Treated: Baseline to Month 24 in Study 156-08-271; Placebo: Baseline to Month 36 in Study 156-04-251
Reported as:
Number · percent change in TKV/participant-years
Annualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271
percent change in TKV/participant-yearsTolvaptan, Delayed Treated (In Study 156-08-271)Placebo (In Study 156-04-251)
Annualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-2714.7795.627
Statistical analysis
  • Tolvaptan, Delayed Treated (In Study 156-08-271) vs Placebo (In Study 156-04-251) · Mixed Models Analysis · p = 0.1080 · Ratio of geometric means (final values): 0.992 · 95% CI 0.982 to 1.002
SecondaryAnnualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271

Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (calculated using CKD-EPI formula) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of eGFR (CKD-EPI) for the participants who received placebo in previous study (156-04-251) to the annualized slope of eGFR (CKD-EPI) for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 who received placebo in previous study and received tolvaptan in this study, as pre-specified in the protocol.

Time frame:
Tolvaptan, Delayed Treated: Baseline to Month 24 in Study 156-08-271; Placebo: Baseline to Month 36 in Study 156-04-251
Reported as:
Number · ml/min/1.73m^2/participant-years
Annualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271
ml/min/1.73m^2/participant-yearsTolvaptan, Delayed Treated (In Study 156-08-271)Placebo (In Study 156-04-251)
Annualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271-3.211-3.572
Statistical analysis
  • Tolvaptan, Delayed Treated (In Study 156-08-271) vs Placebo (In Study 156-04-251) · Mixed Models Analysis · p = 0.2265 · Ratio of geometric means (final values): 0.361 · 95% CI -0.224 to 0.946

Adverse events

Collected over From the signing of the informed consent form until the end of the study regardless of whether the participants were on or off active study medication (Up to approximately 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)5/557 (0.9%)143/557 (25.7%)528/557 (94.8%)
Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)0/314 (0%)79/314 (25.2%)310/314 (98.7%)
Tolvaptan (From Other Studies: Tolvaptan, Early Treated)0/181 (0%)34/181 (18.8%)175/181 (96.7%)
Tolvaptan (From Other Studies: Placebo, Delayed Treated)0/31 (0%)5/31 (16.1%)29/31 (93.5%)
Most frequent serious events
Showing 10 of 202
Most frequent serious events
EventTolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)Tolvaptan (From Other Studies: Tolvaptan, Early Treated)Tolvaptan (From Other Studies: Placebo, Delayed Treated)
Accelerated Idioventricular RhythmCardiac disorders0/5570/3140/1811/31
Haemorrhagic Hepatic CystHepatobiliary disorders1/5570/3140/1811/31
Upper Respiratory Tract InfectionInfections and infestations0/5571/3140/1811/31
Alanine Aminotransferase IncreasedInvestigations2/5573/3145/1811/31
Aspartate Aminotransferase IncreasedInvestigations1/5571/3143/1811/31
Blood Lactate Dehydrogenase IncreasedInvestigations0/5570/3140/1811/31
Essential TremorNervous system disorders0/5570/3140/1811/31
Blood Creatinine IncreasedInvestigations6/5576/3141/1810/31
Renal Cyst InfectionInfections and infestations9/5573/3142/1810/31
Renal Cyst HaemorrhageRenal and urinary disorders6/5574/3142/1810/31
Most frequent other events
Showing 10 of 43
Most frequent other events
EventTolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)Tolvaptan (From Other Studies: Tolvaptan, Early Treated)Tolvaptan (From Other Studies: Placebo, Delayed Treated)
PolyuriaRenal and urinary disorders231/557175/314111/18122/31
NocturiaRenal and urinary disorders145/557111/31494/18117/31
ThirstGeneral disorders261/557161/31480/18113/31
HypertensionVascular disorders160/55782/31442/1812/31
Renal PainRenal and urinary disorders147/55790/31443/1817/31
PolydipsiaMetabolism and nutrition disorders62/55751/31438/1816/31
HeadacheNervous system disorders75/55756/31420/1812/31
FatigueGeneral disorders53/55754/31432/1812/31
NasopharyngitisInfections and infestations83/55755/31418/1814/31
Blood Creatinine IncreasedInvestigations96/55739/31420/1812/31

Baseline characteristics

The enrolled sample consisted of all participants who were enrolled in this open-label study.

Age, Continuous
Age, Continuous(years)Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)Tolvaptan (From Other Studies: Tolvaptan, Early Treated)Tolvaptan (From Other Studies: Placebo, Delayed Treated)Total
Mean42.2 ± 6.942.5 ± 7.240.0 ± 10.135.6 ± 8.741.7 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)Tolvaptan (From Other Studies: Tolvaptan, Early Treated)Tolvaptan (From Other Studies: Placebo, Delayed Treated)Total
Female2541569115516
Male3031589016567
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)Tolvaptan (From Other Studies: Tolvaptan, Early Treated)Tolvaptan (From Other Studies: Placebo, Delayed Treated)Total
Hispanic or Latino24198455
Not Hispanic or Latino47124917227919
Unknown or Not Reported624610109
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)Tolvaptan (From Other Studies: Tolvaptan, Early Treated)Tolvaptan (From Other Studies: Placebo, Delayed Treated)Total
White/Caucasian535302169271033
Black/African American922316
American Indian or Alaska Native00101
Asian325010
Other1084123
08

Study locations

97 sites
  • Otsuka Investigational Site
    Mobile, Alabama 36617, United States
  • Otsuka Investigational Site
    Peoria, Arizona 85381, United States
  • Otsuka Investigational Site
    Tempe, Arizona 85284, United States
  • Otsuka Investigational Site
    Los Angeles, California 90025, United States
  • Otsuka Investigational Site
    Palo Alto, California 94304, United States
  • Otsuka Investigational Site
    San Diego, California 92108, United States
  • Otsuka Investigational Site
    Aurora, Colorado 80045, United States
  • Otsuka Investigational Site
    New Haven, Connecticut 06510, United States
  • Otsuka Investigational Site
    Jacksonville, Florida 32216, United States
  • Otsuka Investigational Site
    Port Charlotte, Florida 33952, United States
  • Otsuka Investigational Site
    Atlanta, Georgia 30322, United States
  • Otsuka Investigational Site
    Augusta, Georgia 30909, United States
  • Otsuka Investigational Site
    Chicago, Illinois 60611, United States
  • Otsuka Investigational Site
    Kansas City, Kansas 66160, United States
  • Otsuka Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Otsuka Investigational Site
    Baltimore, Maryland 21205, United States
  • Otsuka Investigational Site
    Rockville, Maryland 20850, United States
  • Otsuka Investigational Site
    Boston, Massachusetts 02111, United States
  • Otsuka Investigational Site
    Detroit, Michigan 48236, United States
  • Otsuka Investigational Site
    Minneapolis, Minnesota 55404, United States
  • Otsuka Investigational Site
    Rochester, Minnesota 55905, United States
  • Otsuka Investigational Site
    Voorhees, New Jersey 08043, United States
  • Otsuka Investigational Site
    Buffalo, New York 14215, United States
  • Otsuka Investigational Site
    Hawthorne, New York 10532, United States
  • Otsuka Investigational Site
    New York, New York 10021, United States
  • Otsuka Investigational Site
    New York, New York 10032, United States
  • Otsuka Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • Otsuka Investigational Site
    Cincinnati, Ohio 45246, United States
  • Otsuka Investigational Site
    Cleveland, Ohio 44106, United States
  • Otsuka Investigational Site
    Portland, Oregon 97210, United States
  • Otsuka Investigational Site
    Bethlehem, Pennsylvania 18017, United States
  • Otsuka Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Otsuka Investigational Site
    Anderson, South Carolina 29621, United States
  • Otsuka Investigational Site
    Nashville, Tennessee 37205, United States
  • Otsuka Investigational Site
    Nashville, Tennessee 37232, United States
  • Otsuka Investigational Site
    Arlington, Texas 76015, United States
  • Otsuka Investigational Site
    McAllen, Texas 78503, United States
  • Otsuka Investigational Site
    Charlottesville, Virginia 22908, United States
  • Otsuka Investigational Site
    C.a.b.a., Buenos Aires C1429BWN, Argentina
  • Otsuka Investigational Site
    Pilar, Buenos Aires B1629ODT, Argentina
  • Otsuka Investigational Site
    Buenos Aires, C1425APQ, Argentina
  • Otsuka Investigational Site
    Cordoba, 5000, Argentina
  • Otsuka Investigational Site
    Córdoba, X5016KEH, Argentina
  • Otsuka Investigational Site
    St. Leonards, New South Wales 2065, Australia
  • Otsuka Investigational Site
    Westmead, New South Wales 2145, Australia
  • Otsuka Investigational Site
    Woolloongabba, Queensland 4102, Australia
  • Otsuka Investigational Site
    Adelaide, South Australia 5000, Australia
  • Otsuka Investigational Site
    Parkville, Victoria 3050, Australia
  • Otsuka Investigational Site
    Perth, Western Australia 6000, Australia
  • Otsuka Investigational Site
    Brussels, 1090, Belgium
  • Otsuka Investigational Site
    Brussels, 1200, Belgium
  • Otsuka Investigational Site
    Gent, 9000, Belgium
  • Otsuka Investigational Site
    Halifax, Nova Scotia B3H 1V8, Canada
  • Otsuka Investigational Site
    Montreal, Quebec H3A1A1, Canada
  • Otsuka Investigational Site
    Montreal, Quebec H4J1C5, Canada
  • Otsuka Investigational Site
    Bordeaux, 33076, France
  • Otsuka Investigational Site
    Caen Cedex, 14033, France
  • Otsuka Investigational Site
    Lyon Cedex 3, 69437, France
  • Otsuka Investigational Site
    Paris, 75018, France
  • Otsuka Investigational Site
    Reims Cedex, 51092, France
  • Otsuka Investigational Site
    Saint-Etienne Cedex 2, 42055, France
  • Otsuka Investigational Site
    Toulouse Cedex 09, 31059, France
  • Otsuka Investigational Site
    Dresden, 01307, Germany
  • Otsuka Investigational Site
    Dusseldorf, 40210, Germany
  • Otsuka Investigational Site
    Essen, 45147, Germany
  • Otsuka Investigational Site
    Heidelberg, 69120, Germany
  • Otsuka Investigational Site
    Nurnberg, 90471, Germany
  • Otsuka Investigational Site
    Bergamo, 24127, Italy
  • Otsuka Investigational Site
    Milano, 20132, Italy
  • Otsuka Investigational Site
    Modena, 41100, Italy
  • Otsuka Investigational Site
    Napoli, 80131, Italy
  • Otsuka Investigational Site
    Pavia, 27100, Italy
  • Otsuka Investigational Site
    Amsterdam, 1081 HV, Netherlands
  • Otsuka Investigational Site
    Groningen, 9713 GZ, Netherlands
  • Otsuka Investigational Site
    Ciechanów, 06-400, Poland
  • Otsuka Investigational Site
    Krakow, 31-501, Poland
  • Otsuka Investigational Site
    Lodz, 90-153, Poland
  • Otsuka Investigational Site
    Lublin, 20-954, Poland
  • Otsuka Investigational Site
    Szczecin, 70-111, Poland
  • Otsuka Investigational Site
    Warszawa, 04-749, Poland
  • Otsuka Investigational Site
    Wrocław, 50-556, Poland
  • Otsuka Investigational Site
    Bucuresti, 010731, Romania
  • Otsuka Investigational Site
    Bucuresti, 022328, Romania
  • Otsuka Investigational Site
    Iasi, 700504, Romania
  • Otsuka Investigational Site
    Kemerovo, 650029, Russian Federation
  • Otsuka Investigational Site
    St. Petersburg, 191104, Russian Federation
  • Otsuka Investigational Site
    Tomsk, 634063, Russian Federation
  • Otsuka Investigational Site
    Belfast, BT9 7AB, United Kingdom
  • Otsuka Investigational Site
    Birmingham, B15 2TH, United Kingdom
  • Otsuka Investigational Site
    Brighton, BN2 5BE, United Kingdom
  • Otsuka Investigational Site
    Coventry, CV2 2DX, United Kingdom
  • Otsuka Investigational Site
    Edinburgh, EH16 4SA, United Kingdom
  • Otsuka Investigational Site
    Inverness, IV2 3UJ, United Kingdom
  • Otsuka Investigational Site
    London, NW3 2QG, United Kingdom
  • Otsuka Investigational Site
    London, SE5 9RS, United Kingdom
  • Otsuka Investigational Site
    London, SW17 0QT, United Kingdom
  • Otsuka Investigational Site
    Swansea, SA6 6NL, United Kingdom
09

References and documents

Publications

  • Bennett H, McEwan P, Hamilton K, O'Reilly K. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5. PubMed 31014270 ↗
  • Thimmappa ND, Blumenfeld JD, Cerilles MA, Dunning A, Donahue SL, Bobb WO, Zhang HL, Prince MR. Cisterna chyli in autosomal dominant polycystic kidney disease. J Magn Reson Imaging. 2015 Jan;41(1):142-8. doi: 10.1002/jmri.24527. Epub 2014 Jan 27. PubMed 24470398 ↗
  • Blumenfeld JD, Tepler J, Mauer A, Coller B, Bichet DG, Smith B. Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease. Blood. 2011 Jul 14;118(2):474-6. doi: 10.1182/blood-2011-04-347328. No abstract available. PubMed 21757630 ↗

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2010 to primary completion in Feb 2016, 69 months.

Results were first posted in Oct 2021, 5 years 7 months after primary completion. A results delay was requested in Mar 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2010
First posted
Oct 5, 2010
StartActual
May 26, 2010
Primary completionActual
Feb 29, 2016
CompletionActual
Feb 29, 2016
Results delay requested
Mar 2, 2017
Results first posted
Oct 25, 2021
Last update
Oct 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01214421
Responsible party
Sponsor
First posted
Oct 5, 2010
Start date
May 26, 2010
Primary completion
Feb 29, 2016
Completion
Feb 29, 2016
Results posted
Oct 25, 2021
Last update
Oct 25, 2021

Study contacts

Study Director
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion